Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Recombinant protein HIV vaccine candidate to be tested in clinical trials
August 26th, 2005
Epimmune, Inc., (EPMN) announced that the U.S. National Institute of Allergy and Infectious Diseases, a part of the U.S. National Institutes of Health, holds an active investigational new drug application (IND) from the U.S. Food and Drug Administration to test Epimmune's multiepitope recombinant protein vaccine, EP-1043, as a component in vaccines designed to prevent HIV infection. The vaccine candidate will be evaluated in a multicenter, randomized, placebo-controlled, dose-escalation, phase I clinical trial in healthy volunteers conducted by the HIV Vaccine Trials Network (HVTN). The trial consists of two parts: In Part A the safety and maximum...
Source: Drug Week (2005-08-26)
|
